EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Living Alone Is Associated with Discontinuation of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease

Vili Viljaharju, Tuomas Mertsalmi, K Amande M Pauls, Maija Koivu, Johanna Eerola-Rautio, Marianne Udd, Eero Pekkonen

European Neurology · 03.10.2025 · 1-8

DOI: 10.1159/000548570 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Neurology, online erschienen am 03.10.2025. Verfasst von Vili Viljaharju und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland…. Hauptthemen laut MEDLINE: Carbidopa, Levodopa, Parkinson Disease, Antiparkinson Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Levodopa-entacapone-carbidopa intestinal gel (LECIG) is a recently introduced device-aided treatment option for advanced Parkinson’s disease. Data on long-term outcomes remain limited, with only two published studies to date. This study aimed to report long-term outcomes of LECIG treatment, focusing on safety, adverse events, and treatment adherence.

Methods

In this retrospective longitudinal observational single-center study, the medical records of 27 consecutive patients treated with LECIG at Helsinki University Hospital between 2020 and 2024 were analyzed. Adverse events, treatment discontinuations, and medication changes were assessed during the first 2 years of treatment. Clinically significant weight loss was defined as weight loss of >5% over 12 months. Fisher’s exact test was used to assess the association between living situation and treatment discontinuation.

Results

In total, 10 patients (37%) discontinued the treatment, with 6 (60%) within the first year. Living alone was significantly associated with discontinuation (p = 0.033) compared to living with a spouse or in an institution. Three patients died during follow-up from causes unrelated to LECIG treatment. Adverse events were frequent, including inner tube complications requiring 41 inner tube replacements. Clinically significant weight loss was observed in 29% of patients.

Conclusions

In long-term treatment, adverse events with LECIG appear similar to those observed with levodopa-carbidopa intestinal gel (LCIG). However, weight loss and the discontinuation rate appear higher with LECIG. Yet, no direct comparison to LCIG was made in this study. Similar to LCIG, the discontinuation rate is particularly high among patients living alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbidopaLevodopaParkinson DiseaseAntiparkinson AgentsCatecholsNitrilesHumansMaleFemaleDrug CombinationsAgedRetrospective StudiesMiddle AgedGelsLongitudinal Studies

Stichwörter der Autor:innen

Device-aided therapiesLevodopa-entacapone-carbidopa intestinal gelParkinson’s disease

Substanzen

CarbidopaLevodopaDrug Combinationscarbidopa, levodopa drug combinationAntiparkinson AgentsGelsentacaponeCatecholsNitriles

Autor:innen und Institutionen

  • Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland, vili.viljaharju@hus.fi.
  • Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.
  • Department of Gastroenterological Surgery, Helsinki University Hospital, Helsinki, Finland.

Zitieren

APA

Viljaharju, V., Mertsalmi, T., Pauls, K. A. M., Koivu, M., Eerola-Rautio, J., Udd, M., & Pekkonen, E. (2025). Living Alone Is Associated with Discontinuation of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease. European Neurology, 1-8. https://doi.org/10.1159/000548570

Vancouver

Viljaharju V, Mertsalmi T, Pauls KAM, Koivu M, Eerola-Rautio J, Udd M, et al. Living Alone Is Associated with Discontinuation of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease. European Neurology. 2025:1-8. doi:10.1159/000548570

BibTeX
@article{Viljaharju2025,
  author = {Viljaharju, Vili and Mertsalmi, Tuomas and Pauls, K Amande M and Koivu, Maija and Eerola-Rautio, Johanna and Udd, Marianne and Pekkonen, Eero},
  title = {Living Alone Is Associated with Discontinuation of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease},
  journal = {European Neurology},
  year = {2025},
  pages = {1--8},
  doi = {10.1159/000548570}
}
Kostenlos starten →